BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35476295)

  • 1. Targeting IDH-Mutant Glioma.
    Miller JJ
    Neurotherapeutics; 2022 Oct; 19(6):1724-1732. PubMed ID: 35476295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies for IDH-Mutant Gliomas.
    Alshiekh Nasany R; de la Fuente MI
    Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
    Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
    Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
    Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
    J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gray Areas in the Gray Matter:
    van den Bent MJ; Mellinghoff IK; Bindra RS
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-8. PubMed ID: 32186930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
    Richardson LG; Miller JJ; Kitagawa Y; Wakimoto H; Choi BD; Curry WT
    Neurosurg Focus; 2022 Feb; 52(2):E6. PubMed ID: 35104795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.
    Kitagawa Y; Kobayashi A; Cahill DP; Wakimoto H; Tanaka S
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189102. PubMed ID: 38653436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
    Friedrich M; Bunse L; Wick W; Platten M
    Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
    Robinson C; Kleinschmidt-DeMasters BK
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
    Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
    Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
    Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
    Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
    Tang F; Pan Z; Wang Y; Lan T; Wang M; Li F; Quan W; Liu Z; Wang Z; Li Z
    Neurosci Bull; 2022 Sep; 38(9):1069-1084. PubMed ID: 35670952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Pathogenesis of Low-Grade Glioma.
    Bready D; Placantonakis DG
    Neurosurg Clin N Am; 2019 Jan; 30(1):17-25. PubMed ID: 30470401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated progression of IDH mutant glioma after first recurrence.
    Miller JJ; Loebel F; Juratli TA; Tummala SS; Williams EA; Batchelor TT; Arrillaga-Romany I; Cahill DP
    Neuro Oncol; 2019 May; 21(5):669-677. PubMed ID: 30668823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics.
    Yeo KK; Alexandrescu S; Cotter JA; Vogelzang J; Bhave V; Li MM; Ji J; Benhamida JK; Rosenblum MK; Bale TA; Bouvier N; Kaneva K; Rosenberg T; Lim-Fat MJ; Ghosh H; Martinez M; Aguilera D; Smith A; Goldman S; Diamond EL; Gavrilovic I; MacDonald TJ; Wood MD; Nazemi KJ; Truong A; Cluster A; Ligon KL; Cole K; Bi WL; Margol AS; Karajannis MA; Wright KD
    Neuro Oncol; 2023 Jan; 25(1):199-210. PubMed ID: 35604410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.